TCRX tscan.com: Wutah pendapatan triwulanan

Simbol lan logo merek tscan.com (TCRX)

The quarterly revenue growth rate reflects the asset's dynamics, where the value of -76.30 serves as the current metric. TScan Therapeutics (TCRX) is developing a scalable T-cell therapy platform that ensures low production costs alongside high product value. The development of TCR-T drugs relies on partnerships with medical centers, and the successful completion of future clinical trials will provide significant pricing power in personalized oncology.

TCRX Wutah dodolan kuartal marang kuartal tscan.com (04.07.2022 - 20.11.2026)

TScan (TCRX) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:
Analisis umum perusahaan:tscan.com (TCRX)
Barang unggulan TScan Therapeutics Inc

For TScan Therapeutics (TCRX), whose revenues depend on the commercialization of personalized T-cell technologies against solid tumors, this indicator captures the rate of change in quarterly sales volume. By analyzing the quarterly revenue growth trajectory, an investor distinguishes a sustainable financial trend from random fluctuations, allowing for the timely recognition of exhausting growth drivers and an assessment of asset value correction risks.

Pesaing utama

BeiGene Oncology - Wutah pendapatan triwulanan|HALO: Wutah pendapatan kuartal marang kuartal|Revolution Medicines Corp (RVMD) - Wutah pendapatan kuartal marang kuartal|Tingkat wutah pendapatan sajrone kuartal Ascentage Pharma Group International (AAPG)|Wutah pendapatan kuartal marang kuartal CG Oncology, Inc.|Tingkat wutah pendapatan sajrone kuartal UroGen Pharma Corp URGN|Wutah pendapatan triwulanan BCAX|Personalis, Inc. - Wutah dodolan kuartal marang kuartal|Erasca - Wutah dodolan triwulanan|Tambahing pendapatan triwulanan DCTH|YMAB: Wutah dodolan triwulanan|Tingkat wutah pendapatan sajrone kuartal Aura Corp|CADL: Wutah pendapatan triwulanan|ARAY - Tingkat wutah dodolan sajrone kuartal|SLS (SELLAS Life Sciences Group, Inc.) - Wutah pendapatan triwulanan|ACTU: Tambahing pendapatan triwulanan|Wutah pendapatan kuartal marang kuartal citiusonc.com (CTOR)|Tingkat wutah dodolan sajrone kuartal TuHURA Biosciences|Wutah pendapatan kuartal marang kuartal Protara Therapeutics TARA|Fate Therapeutics (FATE) - Tingkat wutah pendapatan sajrone kuartal|WHWK - Wutah pendapatan kuartal marang kuartal|Champions Oncology, Inc. (CSBR) - Wutah dodolan triwulanan|XBIT (XBiotech Inc.) - Wutah dodolan triwulanan|CEL-SCI Corporation (CVM) - Wutah pendapatan triwulanan|Wutah pendapatan kuartal marang kuartal OS Therapies|RADX: Tambahing pendapatan triwulanan|Wutah pendapatan kuartal marang kuartal artivabio.com (ARTV)|Tingkat wutah dodolan sajrone kuartal Adlai Nortye|Wutah pendapatan triwulanan VERU (Veru Corporation)|Owah-owahan dodolan kuartal marang kuartal TPST (Tempest Tx)|XLO: Wutah dodolan triwulanan|renovarobio.com (RENB) - Wutah dodolan triwulanan|Mural Bio (MURA) - Wutah pendapatan kuartal marang kuartal|Kairos Pharma Inc (KAPA) - Wutah pendapatan triwulanan|Wutah dodolan triwulanan OKUR|CytoMed Therapeutics (GDTC) - Tingkat wutah dodolan sajrone kuartal|Wutah dodolan triwulanan CRIS (Curis Inc.)|Wutah pendapatan triwulanan Apollomics Inc. (APLM)|Wutah pendapatan kuartal marang kuartal Tharimmune Corp THAR|Advanced Biomed Corp - Wutah pendapatan kuartal marang kuartal|GNPX: Wutah dodolan triwulanan|Calidi Biotherapeutics, Inc. (CLDI) - Wutah dodolan triwulanan|SBFM: Wutah pendapatan triwulanan|Wutah dodolan triwulanan Xenetic Biosciences Inc.|Wutah pendapatan kuartal marang kuartal Salarius Pharmaceuticals Inc|PPBT: Tambahing pendapatan triwulanan|Wutah pendapatan triwulanan AONC|BGNE (BeOne Medicines) - Tambahing pendapatan triwulanan|Checkpoint Therapeutics, Inc - Wutah dodolan triwulanan|elevationoncology.com (ELEV) - Tingkat wutah pendapatan sajrone kuartal|iCAD Inc. - Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal Ikena Oncology|NTBL: Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal Viracta (VIRX)|MOR (MorphoSys AG) - Wutah pendapatan triwulanan|NAYA: Tambahing pendapatan triwulanan|Wutah pendapatan kuartal marang kuartal Ascentage Pharma Group Ltd (AAPGV)